TMS Co., Ltd. Share Price

Equities

4891

JP3544960002

Biotechnology & Medical Research

Market Closed - Japan Exchange 07:00:00 29/05/2024 BST 5-day change 1st Jan Change
220 JPY -4.76% Intraday chart for TMS Co., Ltd. -7.95% +17.02%

Financials

Sales 2024 * 700M 4.44M 350M Sales 2025 * - Capitalization 8.87B 56.23M 4.43B
Net income 2024 * -80M -507K -39.96M Net income 2025 * -1.28B -8.09M -637M EV / Sales 2024 * 12.7 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-100 x
P/E ratio 2025 *
-6.88 x
Employees 14
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.27%
More Fundamentals * Assessed data
Dynamic Chart
Tennant Minerals Produces 'High-Grade' Concentrates from Bluebird Discovery Samples MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
Jefferies Adjusts TMS’ Price Target to 760 Yen From 730 Yen, Keeps at Buy MT
Tennant Minerals Raises AU$4.8 Million for Drilling, Target Testing; Shares Down 4% MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading MT
Tennant Minerals Finds 23% Copper Concentrate, 1.5G/T Gold at Bluebird Project MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise MT
Tennant Minerals to Commence Next Phase of Drilling at Barkly Project; Shares Down 3% MT
More news
1 day-4.76%
1 week-7.95%
Current month-10.57%
1 month-6.78%
3 months-32.52%
6 months-9.84%
Current year+17.02%
More quotes
1 week
220.00
Extreme 220
236.00
1 month
220.00
Extreme 220
265.00
Current year
171.00
Extreme 171
367.00
1 year
159.00
Extreme 159
460.00
3 years
159.00
Extreme 159
1 188.00
5 years
159.00
Extreme 159
1 188.00
10 years
159.00
Extreme 159
1 188.00
More quotes
Managers TitleAgeSince
Founder 66 16/02/05
President 57 30/04/11
Chief Administrative Officer 54 31/01/18
Members of the board TitleAgeSince
President 57 30/04/11
Director/Board Member 70 30/04/21
Director/Board Member 60 29/02/20
More insiders
Date Price Change Volume
29/05/24 220 -4.76% 134,900
28/05/24 231 0.00% 96,900
27/05/24 231 +1.32% 157,300
24/05/24 228 -0.87% 212,900
23/05/24 230 -1.71% 103,300

Delayed Quote Japan Exchange, May 29, 2024 at 07:00 am

More quotes
TMS Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and marketing of pharmaceuticals. The Company conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
220 JPY
Average target price
760 JPY
Spread / Average Target
+245.45%
Consensus

Annual profits - Rate of surprise